Memantine for OCD: Not Recommended for Routine Use
Memantine is not recommended for routine treatment of OCD, but may be considered as an augmentation strategy specifically in treatment-resistant cases after established first-line and second-line options have failed. 1
Treatment Algorithm for OCD
First-Line Treatment
- SSRIs are the established first-line pharmacological treatment, requiring 8-12 weeks at adequate doses (typically higher than used for depression) 1
- CBT with exposure and response prevention (ERP) is equally first-line, with a number needed to treat of 3 versus 5 for SSRIs 1
Treatment-Resistant OCD (After SSRI Failure)
When approximately 50% of patients fail to respond adequately to first-line treatment 1, the evidence-based hierarchy is:
- Switch to a different SSRI or increase dose beyond maximum recommended 1
- Add CBT if not already implemented (larger effect size than antipsychotic augmentation) 1
- Clomipramine augmentation - demonstrated superiority over quetiapine in head-to-head trials, though carries risk of seizures, arrhythmia, and serotonin syndrome 1
- Antipsychotic augmentation (risperidone or aripiprazole) - most commonly used strategy with established evidence, though only one-third achieve meaningful response 1
Memantine's Limited Role
Memantine is mentioned as a glutamatergic augmentation option only after the above strategies, specifically for treatment-resistant OCD 1. The guideline states: "Memantine augmentation can also be considered in clinical practice, as several trials have demonstrated its efficacy in SSRI augmentation for patients with treatment-resistant OCD" 1.
Critical Evidence Limitations
The most recent systematic review (2026) reveals memantine does not produce statistically significant symptom reduction overall (pooled mean difference -3.74 points, 95% CI -9.95 to 2.47) with very high heterogeneity 2. While treatment-resistant subgroups showed larger effects (≈ -8.85 points), this was based on only two trials and remains hypothesis-generating rather than definitive 2.
Major methodological concerns undermine the evidence base:
- All positive trials emerged from the same geographical region, limiting generalizability 3
- Studies presented completer analyses rather than intention-to-treat, compromising validity 3
- Small sample sizes and strong geographical clustering 4
- The 2019 meta-analysis showing 81% response rates has been critically challenged for these validity issues 3
Practical Considerations
If memantine is considered in truly refractory OCD:
- Dose: 20 mg/day appears most effective 5
- Duration: Minimum 8 weeks needed to assess response 5
- Tolerability: Generally well-tolerated; nausea most common side effect, mild rash risk increased (RR 7.00) 6, 5
- Context: Only after SSRIs, CBT, clomipramine augmentation, and antipsychotic augmentation have been inadequate
Critical Pitfall
Do not use memantine as a routine augmentation agent. The FDA label for memantine only covers Alzheimer's disease 7, making OCD use entirely off-label. The striking benefits reported in early meta-analyses have been methodologically challenged and not replicated in rigorous recent systematic reviews 2, 4, 3.
The evidence supports memantine only as a last-resort option in treatment-refractory OCD when established augmentation strategies (antipsychotics, clomipramine) are unsuitable or have failed 1, 2, 4.